Tumor Lysis Syndrome as a Consequence of Chronic Lymphocytic Leukemia Treatment With Fludarabine and Rituximab

Firas Yazigi, Anuradha Kolluru, Ayad M Al-katib

Abstract

A seventy-nine year old Caucasian male with a diagnosis of chronic lymphocytic leukemia presented with acute tumor lysis syndrome after treatment with two courses of fludarabine and one course of rituxan. In this article we report this rare complication, which has been reported only few times in the literature, and discuss the ways to prevent it from happening.

Keywords: Tumor lysis syndrome; Chronic lymphocytic leukemia; Treatment; Fludarabine; Rituximab

Introduction

Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). It is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin. CLL is the most common lymphoproliferative disorder and the most common leukemia in the western world and occurs mainly in older age population. It usually progresses slowly over an extended period of time and is monitored by following the lymphocytosis, peripheral adenopathy and splenomegaly that ensue. Treatment is rendered to those patients who become symptomatic or when they become anemic or thrombocytopenic.

Acute tumor lysis syndrome is the term applied to a group of metabolic complications that usually occur after the treatment of neoplastic disorders. The findings that may be seen include hyperphosphatemia, hypocalcemia (due to precipitation of calcium phosphate), hyperuricemia, hyperkalemia, and acute renal failure [1].

Tumor lysis syndrome after fludarabine therapy is extremely uncommon, but may be associated with significant morbidity and mortality.

Case Report

A 79 year-old Caucasian male with past medical history significant for chronic lymphocytic leukemia (CLL), presented with change in mental status and confusion.

The patient was diagnosed with CLL in 2004, but did not require treatment at that time. He was free of symptoms until a year later when he became fatigued and short of breath and was found to have increased white cell count of 23,000/mm3. Chemotherapy was initiated at that point, and the patient received 6 cycles of chlorambucil/prednisone between February 2005 and February 2006.

The patient responded well to treatment with no complications and was being observed thereafter with no intervention until he became dyspneic again in September 2006 and was found to have large right pleural effusion consistent with CLL. At that point the decision was made to start treatment with rituxan and fludarabine.

The patient received 375 mg/m2 (750 mg) of rituxan and 25 mg/m2 (50 mg) of fludarabine as a first dose, and on the next day he received a second dose of fludarabine. Later that day he became very weak, lethargic and difficult to arouse so he was admitted to the hospital for further evaluation.

The patient was intubated and transferred to the MICU secondary to respiratory failure and progressive confusion. He was started on aggressive IV hydration, and Elitek (Rasburicase) 3 mg as a single dose.

Manuscript accepted for publication June 9, 2011

*Department of Internal Medicine, St. John Hospital and Medical Center, Michigan, USA

© Corresponding author: Firas Yazigi, Email: firas.yazigi@stjohn.org
doi:10.4021/jmc239w
Chest tube was also placed to drain the large pleural effusion. Continuous venovenous hemodialysis (CVVHD) was initiated by nephrology service to enhance recovery process. The patient’s condition improved remarkably in the following days and upon his full recovery he was transferred to pulmonary rehabilitation facility.

Discussion

The tumors most frequently associated with the tumor lysis syndrome are the high grade, very aggressive lymphomas, such as Burkitt lymphoma, and the leukemias, particularly acute lymphoblastic leukemia (ALL) and less often acute myeloid leukemia [1-3].

Since the original description of predominantly acute uric acid nephropathy following the treatment of lymphoma and leukemia [1], the presentation of this syndrome has changed in two ways: 1) The introduction of allopurinol, and to a lesser extent uricase, before the onset of antitumor therapy has reduced, but not eliminated, the incidence of acute uric acid nephropathy. Acute renal failure following therapy is now more frequently associated with severe hyperphosphatemia. 2) Spontaneous acute renal failure prior to therapy is now more commonly recognized and is usually due to acute uric acid nephropathy. These patients have increased uric acid production and hyperuricosuria due to the high rate of tumor cell turnover.

The tumor lysis syndrome should be suspected in patients with a large tumor burden who develop acute renal failure in the presence of marked hyperuricemia (greater than 15 mg/dL or 893 \( \mu \text{mol/L} \)) and/or hyperphosphatemia (greater than 8 mg/dL or 2.56 mmol/L). These levels are in contrast to most other forms of acute renal failure in which the plasma uric acid concentration is less than 12 mg/dL (714 \( \mu \text{mol/L} \)) and the plasma phosphate level is less than 6 mg/dL (1.92 mmol/L) [4].

While only 6 cases of TLS associated with fludarabine therapy have been reported since 1989 (up to 2011) [5, 6], cautious monitoring of patients treated with fludarabine should be undertaken, even after completion of the chemotherapy course. The same applies to the patients who are about to be treated with rituxan (especially after the first dose), since there have been two cases reported of Rituxan-induced TLS in CLL patients in the literature.

Patients about to receive chemotherapy or radiation for a malignancy with rapid cell turnover should be pretreated, if possible, for at least two days with allopurinol plus fluid loading (with saline and possibly mannitol) to maintain a high urine output (greater than 2.5 L/day) [7]. Reversible forms of renal insufficiency (e.g., volume contraction, hypercalcemia, urinary tract obstruction) should be corrected prior to therapy.

For those unable to receive oral medications, intravenous allopurinol was approved in 1996 by the FDA under orphan drug status, and has been commercially available for this indication since 1999 (Aloprim, Nabi, Boca Raton, FL) [8, 9]. A review of its use in over 1100 patients found that this preparation was both safe and effective.

TLS after fludarabine therapy is extremely uncommon, but may be associated with significant morbidity and mortality. Hence it is important to anticipate such a complication before initiating therapy with fludarabine and rituxan, and apply all available preventive measures to reduce its incidence.

Conflict of Interest

None

References